BioNTech's SWOT analysis: oncology pipeline, cash boost stock outlook
BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...
J.P. Morgan Sticks to Their Buy Rating for Ascendis Pharma (ASND)
J.P. Morgan analyst Jessica Fye maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00.
J.P. Morgan Remains a Buy on Intra-Cellular Therapies (ITCI)
In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...